Catecholamine treatment for shock--equally good or bad?
Bloomsbury Institute of Intensive Care Medicine, Wolfson Institute for Biomedical Research and Department of Medicine, University College London, London WC1E 6BT, UK. The Lancet
(Impact Factor: 45.22).
09/2007; 370(9588):636-7. DOI: 10.1016/S0140-6736(07)61317-8
Available from: Anthony C Gordon
- "The calcium and anti-inflammatory actions of levosimendan provide a strong biological rationale for its use in sepsis. In addition, conventional vasoactive support using catecholamines such as norepinephrine and dobutamine may result in sympathetic nervous system overstimulation and a range of adverse effects . Evidence of a lack of benefit from trials comparing different catecholamine regimens , increased mortality in patients exposed to a greater vasopressor load , the observation of higher plasma catecholamine levels in non-survivors compared to survivors of critical illness , and emerging evidence that beta-blockade may play a role if patients are receiving high-dose catecholamines  all provide further evidence of possible harm from conventional catecholamine therapy. "
[Show abstract] [Hide abstract]
Organ dysfunction consequent to infection (‘severe sepsis’) is the leading cause of admission to an intensive care unit (ICU). In both animal models and early clinical studies the calcium channel sensitizer levosimendan has been demonstrated to have potentially beneficial effects on organ function. The aims of the Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS) trial are to identify whether a 24-hour infusion of levosimendan will improve organ dysfunction in adults who have septic shock and to establish the safety profile of levosimendan in this group of patients.
This is a multicenter, randomized, double-blind, parallel group, placebo-controlled trial. Adults fulfilling the criteria for systemic inflammatory response syndrome due to infection, and requiring vasopressor therapy, will be eligible for inclusion in the trial. Within 24 hours of meeting these inclusion criteria, patients will be randomized in a 1:1 ratio stratified by the ICU to receive either levosimendan (0.05 to 0.2 μg.kg-1.min-1 or placebo for 24 hours in addition to standard care. The primary outcome measure is the mean Sequential Organ Failure Assessment (SOFA) score while in the ICU. Secondary outcomes include: central venous oxygen saturations and cardiac output; incidence and severity of renal failure using the Acute Kidney Injury Network criteria; duration of renal replacement therapy; serum bilirubin; time to liberation from mechanical ventilation; 28-day, hospital, 3 and 6 month survival; ICU and hospital length-of-stay; and days free from catecholamine therapy. Blood and urine samples will be collected on the day of inclusion, at 24 hours, and on days 4 and 6 post-inclusion for investigation of the mechanisms by which levosimendan might improve organ function. Eighty patients will have additional blood samples taken to measure levels of levosimendan and its active metabolites OR-1896 and OR-1855. A total of 516 patients will be recruited from approximately 25 ICUs in the United Kingdom.
This trial will test the efficacy of levosimendan to reduce acute organ dysfunction in adult patients who have septic shock and evaluate its biological mechanisms of action.
Current controlled trials ISRCTN12776039 (19 September 2013)
Trials 06/2014; 15(1):199. DOI:10.1186/1745-6215-15-199 · 1.73 Impact Factor
Available from: Primrose P E Freestone
- "Other factors recognized as leading to increased risk of infection involve invasive treatment procedures, particularly use of endotracheal tubes (with mechanical ventilation), urinary catheters, surgical drains, and IV catheter lines. An additional risk factor is now recognized as coming from the inotrope medications patients are given . This view came about because catecholamine inotropes have been shown to be involved in staphylococcal colonization of indwelling medical devices such as IV lines due to their ability to stimulate staphylococcal growth and biofilm formation [14, 51–53]. "
[Show abstract] [Hide abstract]
ABSTRACT: It is clear that a dialogue is occurring between microbes and their hosts and that chemical signals are the language of this interkingdom communication. Microbial endocrinology shows that, through their long coexistence with animals and plants, microorganisms have evolved sensors for detecting eukaryotic hormones, which the microbe uses to determine that they are within proximity of a suitable host and to optimally time the expression of genes needed for host colonisation. It has also been shown that some prokaryotic chemical communication signals are recognized by eukaryotes. Deciphering what is being said during the cross-talk between microbe and host is therefore important, as it could lead to new strategies for preventing or treating bacterial infections.
12/2013; 2013(3):361073. DOI:10.1155/2013/361073
Available from: Maja Surbatovic
- "Better definition of lowest acceptable blood pressure in individual patients is also needed to minimize the harmful effects of excessive catecholamine dosing. Additionally, the use of concurrent medications that contribute to hypotension (e.g., excess sedative dosing) and vascular hyporeactivity (e.g., etomidate) should be limited . Guidelines recommend mean blood pressure values ≥65 mmHg for patients with severe sepsis, but with no firm scientific basis. "
[Show abstract] [Hide abstract]
ABSTRACT: Critically ill patients suffer a high rate of nosocomial infection with secondary sepsis being a common cause of death. Usage of antibiotics and catecholamines is often necessary, but it can compromise complex immune response to infection. This review explores influence of these life-saving drugs on host immune response to severe infection.
The Scientific World Journal 09/2013; 2013:961852. DOI:10.1155/2013/961852 · 1.73 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.